Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 447 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo - oral form Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

4-day Plaque Accumulation Model Evaluating Compound Containing Gum

NCT06984744
View directory record Official record
Conditions
Dental Plaque Accumulation
Interventions
MIIP-E2 containing gum, placebo gum without MIIP-E2
Device
Lead sponsor
Lactea Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Melatonin on Cardiovascular and Thermoregulatory Responses to Stress

NCT07138443
View directory record Official record
Conditions
Stress, Mental Stress
Interventions
Melatonin 3 MG Oral Tablet, Placebo Oral Tablet
Dietary Supplement
Lead sponsor
Baylor University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Selenium Intervention on Inflammation in Older Adults

NCT01289925
View directory record Official record
Conditions
Inflammation
Interventions
Selenium, Sugar Pill Placebo
Dietary Supplement · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
70 Years to 110 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 19, 2026, 10:34 AM EDT
Withdrawn Phase 3 Interventional

Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients

NCT03968640
View directory record Official record
Conditions
Multiple Organ Failure
Interventions
CoQ10, Placebo
Dietary Supplement
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)

NCT00920621
View directory record Official record
Conditions
Asthma
Interventions
Vitamin D 3 cholecalciferol, Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
876 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Recruiting Phase 4 Interventional

Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?

NCT06046859
View directory record Official record
Conditions
Musculoskeletal Injury
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

NCT01110408
View directory record Official record
Conditions
Complicated Urinary Tract Infections or Pyelonephritis
Interventions
Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Tolerability of BAF312 in Patients With Polymyositis

NCT01801917
View directory record Official record
Conditions
Polymyositis
Interventions
Placebo, BAF312
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

An Interventional Study of Infigratinib in Children With Hypochondroplasia

NCT06873035
View directory record Official record
Conditions
Hypochondroplasia
Interventions
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain

NCT05003063
View directory record Official record
Conditions
Visual Perception, Attention, Information Processing, Cholinergic System
Interventions
Donepzil, Placebo oral tablet
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

NCT04622332
View directory record Official record
Conditions
Corona Virus Infection
Interventions
SIR1-365, Matching Placebo
Drug
Lead sponsor
Sironax USA, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
West Palm Beach, Florida • Peoria, Illinois • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

NCT00616148
View directory record Official record
Conditions
Epilepsy
Interventions
YKP3089, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

NCT03600805
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 19, 2026, 10:34 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Glutathione vs. Curcumin Clinical Trial

NCT02848417
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Curcumin, Glutathione, Placebo
Drug · Other
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
35 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

NCT01500109
View directory record Official record
Conditions
Cleft Palate
Interventions
Oral acetaminophen, Ofirmev®, Opioid only
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
5 Months to 5 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

NCT03301298
View directory record Official record
Conditions
Healthy
Interventions
SXC-2023, Placebo oral capsule
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 3 Interventional Results available

Statins for Acutely Injured Lungs From Sepsis

NCT00979121
View directory record Official record
Conditions
Sepsis, Acute Lung Injury
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
40
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Not applicable Interventional

The Effects of an Orally-Administered Probiotic on Vaginal Symptoms

NCT07829861
View directory record Official record
Conditions
Vaginal Odor
Interventions
Orally-administered probiotic, Placebo
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03325010
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 19, 2026, 10:34 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 19, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

NCT04410978
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 19, 2026, 10:34 AM EDT